Quality of life in adults with muscular dystrophy by Jacques, Matthew F. et al.
Article
Quality of life in adults with muscular dystrophy
Jacques, Matthew F., Stockley, Rachel, Onambele-Pearson, Gladys 
L., Reeves, Neil D., Stebbings, Georgina K., Dawson, Ellen A., 
Groves, Lynne and Morse, Christopher I.
Available at http://clok.uclan.ac.uk/29326/
Jacques, Matthew F., Stockley, Rachel, Onambele­Pearson, Gladys L., Reeves, Neil D., Stebbings,  
Georgina K., Dawson, Ellen A., Groves, Lynne and Morse, Christopher I. (2019) Quality of life in 
adults with muscular dystrophy. Health and Quality of Life Outcomes, 17 (1).  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.1186/s12955-019-1177-y
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/research/ 
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained 
by the individual authors and/or other copyright owners. Terms and conditions for use 
of this material are defined in the http://clok.uclan.ac.uk/policies/
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
RESEARCH Open Access
Quality of life in adults with
muscular dystrophy
Matthew F. Jacques1* , Rachel C. Stockley2, Gladys L. Onambele-Pearson1, Neil D. Reeves1, Georgina K. Stebbings1,
Ellen A. Dawson3, Lynne Groves4 and Christopher I. Morse1
Abstract
Background: Muscle weakness is a defining characteristic of Muscular Dystrophy (MD); however, yet while
speculated, objective measures of muscle weakness has not been reported in relation to quality of life in adults
with MD.
Objectives: 1) compare the self-reported QoL of adults with Duchenne MD (DMD), Beckers MD (BMD), Limb-Girdle
MD (LGMD) and Fascioscapulohumeral MD (FSHD, and a non-MD (CTRL) group; 2) present and compare between
groups measures of Impairment (Muscle Strength and Activities of Daily Living) and Perception (Fatigue, Pain and
Self-Efficacy); and 3) identify associations between QoL domains and measures of Impairment and Perception (See
above).
Methods: Seventy-Five males, including MD classifications DMD, BMD, LGMD, FSHD and CTRL, completed measures
for QoL, Knee-Extension Maximal Voluntary Contraction (KEMVC), Fatigue, Pain, Self-Efficacy and Activities of Daily
Living (ADL).
Results: QoL was lower across many domains in MD than CTRL. FSHD scored lower than DMD for mental
wellbeing domains. KEMVC associated with Physical-Function domain for BMD. Pain, Self-Efficacy and ADLs
associated with QoL domains, with Fatigue the most consistently associated.
Conclusion: The present study identified differences between MD classifications within self-perceptions of mental-
health. Muscle weakness is a defining feature of MD; however, it doesn’t define QoL in adults with MD. A greater
understanding of mental wellbeing, independence, and management of fatigue and pain, are required to improve
QoL for adults with MD.
Keywords: Quality of life, Strength, Fatigue, Activities of daily living, Self-efficacy, Muscular dystrophy
Background
Muscular Dystrophy (MD) is a group of neuromuscular
conditions, characterised by progressive muscle wasting
and weakness [1]. Duchenne MD (DMD), Becker MD
(BMD), Limb-Girdle MD (LGMD) and Facioscapulo-
humeral MD (FSHD) are 4 types of MD where the im-
pairments are uniquely comparable within the broader
MD classifications, by being associated with defects in
the proteins of the sarcoglycan complex [2–6]. While
these MD types are comparable in impairments
associated with the sarcoglycan complex, their presenta-
tion and clinical progression are specific to their own
condition, and therefore each MD type should be con-
sidered independently. DMD is the most severe of the
MD described here, with loss of ambulation typically by
the age of 12, by comparison BMD is broadly a milder
and more varied condition, with loss of ambulation typ-
ically not until adulthood [7, 8]. LGMD and FSHD are
classically characterised by local weakness consistent
with their names [9, 10]. Irrespective of condition, all
MDs typically present with declining muscle strength
and eventual loss of ambulation [11], which are likely to
reduce independence, and the self-perception of physical
function [12]. The loss of muscle strength and function
is commonly seen as a defining feature of MD, despite
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however, QoL reported as typically lower in adults with
MD [13–17], the impact on perceived QoL through ob-
jectively methods of muscle strength remain unreported
in adults with MD [18].
QoL represents an individual’s perception of their
physical, mental and social functioning [19], and is a
meaningful measure of how a clinical condition may be
impacting an individual. QoL has been reported
previously in adults with MD, however, when multiple
classifications of MD have been included within the
same report, classifications have been typically pooled
[13, 14, 20, 21]. Similarly, reviews of QoL in adults with
MD have typically grouped MD within ‘neuromuscular
disorders’ or ‘muscle disease’ groups, whereby evidence
is diluted by other conditions, such as myotonic dys-
trophy, idiopathic inflammatory myositis and inclusion
body myositis [15, 22]. The variations in mutative-
genetic cause [3], and clinical progression [7–10], of
each condition strongly suggest that each classification
should be recognised and assessed independently, in
order to detect possible differences in QoL between
classifications of MD. In addition, greater understanding
of the factors associated with QoL within different
classifications of MD is required.
Given the progressive loss of strength and function
associated with MD [23], research to date has focussed
on the physical aspects of individual’s lives, such as
respiratory function [24] and muscle strength [18]. Asso-
ciations between QoL and objective measures of muscle
strength however, remain largely unreported within
adults with MD [23], with limited previous research
using functional scales which lack sensitivity [14, 25, 26].
By comparison, loss of muscle strength has previously
been correlated with QoL in children with DMD [18].
More broadly in MD, a loss of muscle strength limits
the ability to walk and perform functional tasks [11, 27],
which are both facets contributing to QoL. In addition,
increased BMI has been reported previously in adults
with MD [11, 28], and shown to impact not only
function [29], but also effect psychological wellbeing in
overweight individuals [30]. Alternatively, psychological
aspects such as self-efficacy [31], an individual’s confi-
dence in their ability to overcome problems [32], may
provide a greater insight into QoL than physical impair-
ment alone and has been shown to be positively associ-
ated with QoL in other clinical conditions [33, 34].
Other perceived measures, including fatigue and pain,
are also likely to impact upon QoL in all MD groups,
and have previously been shown to impact QoL in adults
with DMD and FSHD [16, 25, 35], and have been
proposed when discussing neuromuscular and muscle
diseases more broadly [15, 22], however have not
reported in adults with BMD or LGMD.
This study therefore, aimed to 1) compare the self-
reported QoL of adults with DMD, BMD, LGMD and
FSHD, and a non-MD control (CTRL) group; 2) present
and compare between groups measures of Impairment
(Muscle Strength and Activities of Daily Living) and
Perception (Fatigue, Pain and Self-Efficacy); and 3)
identify associations between QoL domains and mea-
sures of Impairment and Perception (See above).
Methods
Seventy-five adult males volunteered to participate in
this study (n = 15 DMD, n = 18 BMD, n = 12 LGMD, n =
14 FSHD, n = 16 non-MD controls (CTRL), Table 1).
Participants were grouped by their dystrophic condition.
All participants with MD were recruited from, and
tested at, The Neuromuscular Centre (Winsford, UK).
None were taking part in a structured training
programme, however all were receiving once weekly or
fortnightly physiotherapy treatment. Control partici-
pants, were recruited from the general population, were
free from any health conditions, self-reported as being
recreationally active (undertaking no more than 1 h of
moderate physical activity per week), and were not
undertaking any structured sport/exercise training
programme. CTRL participants were tested at the local
university campus, using identical methods and equip-
ment as the MD participants (other than height and
body mass, see below). None of the MD or CTRL partic-
ipants reported any change in their activity levels or
Table 1 Participants Characteristics
DMD BMD LGMD FSHD CTRL
n 15 18 12 14 16
Age (Years) 24.2 ± 6.1 B***,LG***,F***,C* 42.4 ± 13.5 41.6 ± 11.7 47.1 ± 11.1 C* 35.4 ± 12.7
Stature (cm) 172.0 ± 4.3 177.4 ± 6.0 179.6 ± 7.2 178.6 ± 8.1 177.5 ± 9.3
Mass (Kg) 73.1 ± 14.6 B*,LG**,F* 86.5 ± 20.3 97.0 ± 18.1 C* 86.0 ± 11.2 81.1 ± 18.2
Ambulant 0/15 10/18 3/12 10/14 16/16
BMI (kg/m2) 25.5 ± 4.1 27.3 ± 6.2 29.4 ± 26.6 26.6 ± 3.4 25.5 ± 3.7
Participants’ anthropometric characteristics
DMD Duchenne Muscular Dystrophy, BMD Beckers Muscular Dystrophy, LGMD Limb-Girdle Muscular Dystrophy, FSHD Facioscapulohumeral Muscular Dystrophy,
cm centimetres, Kg Kilograms, BMI Body Mass Index, B denotes significant difference from BMD; LG denotes significant difference from LGMD; F denotes significant
difference from FSHD; C denotes significant difference from CTRL; * denotes P < .05; ** denotes P < .01; *** denotes P < .001
Jacques et al. Health and Quality of Life Outcomes          (2019) 17:121 Page 2 of 10
physiotherapy provision in the 3-months prior to inclu-
sion in this study. Ethical approval was obtained through
the Sports and Exercise Science Ethics Committee,
Manchester Metropolitan University, and all participants
provided informed written consent forms prior to
participation. All procedures complied with the World
Medical Association Declaration of Helsinki [36].
Procedures
All participants were tested in a single testing session.
The same equipment was used for all participants, with
the exception of seated scales for body mass measures in
non-ambulatory MD participants. All participants were
assessed in a seated position to ensure consistency.
Anthropometric measures were performed first, followed
by a strength assessment. Questionnaires for quality of
life, activities of daily living, self-efficacy, fatigue and
pain were completed independently. The principal
investigator was present to aid with any questions, or in
some cases, to tick the desired box for participants with
limited upper-limb function.
Anthropometrics
Control participants’ mass was measured whilst standing
(unshod) using digital scales (Seca model 873, Seca,
Germany). MD participants were weighed in digital
seated scale (6875, Detecto, Webb City, Mo, USA).
Slings, shoes, splints etc. were weighed separately and
subtracted from the gross weight. All participants stature
was calculated as point to point (index finger, elbow,
shoulder and across midline) to replicate a previously
used method on non-ambulatory participants [28, 37]. A
correction of 3.5% was applied to the raw data, consist-
ent with regression data from Caucasian males in order
to account for the known discrepancy between height
and arm span measures [38].
Body Mass Index (BMI) was calculated using the
following equation [39]:
BMI
Kg
m2
 
¼ Body Mass Kgð Þ Height2 m2 
Participants’ age, mass, stature, ambulatory status and
BMI are presented in Table 1.
Quality of life
All participants completed the SF-36v2 questionnaire, a
reliable and validated measure, with eight domains of
quality of QoL [40, 41]. The constructs for the domains
of QoL are Physical Functioning, Role-Functioning
Physical, Role-Functioning Emotional, Social Function-
ing, Bodily Pain, Mental Health, Vitality and General
Health [42]. All measures are scored out of 100, with
higher scores representative of better health, better
function and less pain. The SF-36v2 has been used
and validated extensively in the general population;
however, it has also been used in dystrophic popula-
tions [13, 24, 25, 43]. In addition to the eight domains
within the SF-36v2, data is also presented as Total Mental
and Total Physical component scores. All data was
analysed using Health Outcomes Scoring Software 4.5
(QualityMetric Health Outcomes™, Lincoln, United
Kingdom).
Impairment
Muscle strength
Knee extension maximal voluntary contraction (KEMVC)
torque was measured using methods replicative to
Quantitative Muscular Assessment, as is commonly used
in dystrophic studies [27, 44], for which a full description
and reliability data have been reported previously [11].
Below is an overview of the measurement of KEMVC.
Despite some participants being non-ambulant, testing
was designed to allow all participants to participate, of
which all participants were able to produce a measurable
force using this technique.
The self-reported dominant leg was measured, if
participants were unable to recognise a dominant leg,
the right was used. All participants were assessed in a
seated position with hips and knees at 90°, with non-
ambulant participants remaining in their manual or
power-wheelchair. A strap with a load cell (Zemic, Eten-
Leur, Netherlands) attached was fastened around the
ankle and perpendicularly to a weighted support bar.
The strap length was shortened until the strap was taut
between the load cell and limb, while maintaining limb
position. All participants were verbally encouraged to
extend their leg as hard as possible throughout their
maximal effort. The load cell was calibrated prior to
every testing session. The load cell was connected to an
analogue-digital converter and displayed in real-time on
a computer screen, using a self-coded program (MyLab-
View, National Instruments, Berkshire, UK).
Three trials were performed per participant, with one
minute breaks between trials due to the high fatigability
associated with these conditions [45]. The peak
KEMVC force (N) was converted to torque (N.m),
with KEMVC torque used for analysis, as the product
of force and lever arm, measured from the axis of ro-
tation at the knee joint to the point of linear force
(centre of strap) [46].
Activities of daily living
Activities of Daily Living (ADL) were assessed using the
22-item Nottingham Extended ADL Scale (NEADL).
Respondents record what they had done over the last
few weeks, with possible answers “Not at all”, “With
help”, “On your own with difficulty”, or “On your own”.
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To increase sensitivity, scores were allocated using a
Likert scale “0–1–2-3” [47, 48], rather than “0–0–1-1”,
therefore scores ranged from 0 to 66 with higher
scores representing greater independence. The
NEADL has been previously validated in other clinical
conditions [49, 50].
Perceptions
Fatigue
The 8-item Fatigue Severity subscale of the Checklist
Individual Strength (CIS) was used for analysis (hereafter
referred to as CIS Severity). Each item was scored on a
7-point Likert scale where higher scores indicate a
higher degree of fatigue severity. Reliability of CIS has
been previously reported as good (α = .82–92) [51] and
has good discriminate validity [52]. The CIS has been
used previously to identify chronic fatigue in adults with
FSHD [53, 54].
Pain
A Visual Analog Scale (Pain VAS) of pain was used to
quantify the level of pain felt by participants over the 7
days preceding assessment. VAS is a common method of
pain assessment [55] and used in many conditions
[25, 56, 57]. Participants were given a 10 cm straight
line, with at one end “No Pain”, and the other “Worst
Possible Pain”, and instructed to mark where, on
average, they felt their pain over the preceding 7 days
was on the scale. The mark was then measured and
presented as distance (cm) from the “No Pain” end.
Self-efficacy
The General Self Efficacy Scale (GSES) [58] was considered
most suitable for our population as most Self-Efficacy
scales are rehabilitative, and focus on improvements or
return to physical status, and were deemed invalid for a
degenerative muscle condition. In contrast, the GSES fo-
cuses on overcoming problems rather than rehabilitation.
The GSES is a 10-item scale, using a 4-point Likert Scale
for each question. Possible responses to questions are: not
at all true (1), hardly true (2), moderately true (3), and
exactly true (4), resulting in a total score between 10 and
40. High reliability, stability, and construct validity have
been confirmed previously [59–61].
Statistical analysis
All analysis was performed using IBM SPSS Statistics
v21 software. The critical level of statistical significance
was set at 5%. All data is presented as mean ± SD, unless
stated otherwise in the table legend. Tests for parametri-
city were performed upon participants’ anthropometrics
and KEMVC, with all questionnaire data interpreted as
non-parametric. All data, except for stature was para-
metric. Kruskal Wallis test was used to compare
between groups, with post-hoc Mann-Whitney U pair-
wise comparisons used where appropriate. As all groups
are independent and do not interact, no bonferroni cor-
rection was used during post-hoc analysis. Stature was
compared between groups using a one-way ANOVA,
and Tukey’s used for post-hoc comparison. Spearman’s
rank correlation analysis were used to identify associa-
tions between variables and domains of QoL with
±.30–.49 considered weak, ±.50–.69 considered moder-
ate and ± .70+ considered strong.
Results
Participant characteristics
Data detailing participant characteristics is summarised
in Table 1. DMD were younger than all other groups,
and FSHD were older than CTRL. No differences were
found between groups for stature. DMD were lighter
than other MD groups, and LGMD were heavier than
CTRL. No differences were found between groups for
BMI.
Quality of life
Data detailing QoL in the study sample is summarised
in Table 2. For clarification lower scores are indicative of
lower QoL, e.g. a lower Bodily Pain domain in MD than
CTRL, reflects higher reported pain in MD than CTRL.
The Physical Function and Role Physical domains were
lower in all MD groups compared to CTRL. Within MD,
the Physical Function domain was lower in DMD than
BMD and FSHD. The Role Physical domain was higher
in DMD than FSHD. The Vitality domain was lower in
BMD and FSHD compared to CTRL. In addition, DMD
reported a higher Vitality domain than FSHD. No other
differences were found between groups for Vitality.
Within the Role Emotional domain, DMD, BMD and
FSHD were lower than CTRL. The Role Emotional
domain, was higher in LGMD than FSHD. No other
differences were found between groups for the Role
Emotional domain.
The Bodily Pain, Social function and General Health
domains were lower in all MDs compared to CTRL, with
no differences found between MD groups. The Total
Physical domain was lower in all MDs compared to
CTRL. No other differences were found between groups
for the Total Physical domain. No differences were
found between groups for Total Mental domain. Total
SF6D domain was lower in all MDs compared to CTRL.
No other differences were found between groups for
Total SF6D domain.
Impairment and perceptions
The measures of impairment and perceptions are
detailed in Table 3. KEMVC was less in DMD, BMD,
LGMD groups compared to CTRL. KEMVC was less in
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DMD than BMD, LGMD and FSHD groups. No other
KEMVC differences were found between groups. ADL
was lower in DMD than all other groups. Compared to
CTRL, ADL was lower in BMD, LGMD and FSHD, re-
spectively. No other differences were found between
groups.
CIS Severity was higher in all MD groups compared to
CTRL. CIS Severity was higher in FSHD than DMD and
BMD groups. No other differences were found between
groups for CIS Severity. All MD groups reported higher
levels of VAS Pain compared to CTRL participants.
There were no differences in pain between MD groups.
Self-Efficacy was not different between groups.
QoL correlations
The following brief description of associations (or lack
thereof ), are summarised in Table 4 below.
BMI
The Social Function domain was moderately associ-
ated with BMI, while the Vitality domain, Total Men-
tal Score and SF6D were all strongly associated with
BMI, in LGMD. No other associations were identified
with BMI.
Impairment
Physical Function domain was associated with ADL,
moderately in DMD and BMD, and strongly in FSHD.
The Physical Function and Social Function domains
were also moderately associated with KEMVC in BMD.
The Vitality, Bodily Pain and General Health domains
were moderately associated with ADL in DMD. No
other associations were identified with measures of
Impairment.
Perception
The Role Physical domain was strongly associated with
CIS Severity in DMD and FSHD. In addition, Role
Physical domain was also moderately associated with
Self-Efficacy in DMD. The Bodily Pain domain was
associated with VAS Pain in BMD (strong) and FSHD
(moderate).
The General Health domain was moderately associated
with CIS Severity in DMD, BMD and LGMD, and VAS
Pain in BMD.
Table 3 Measures of Impairment and Perception
DMD BMD LGMD FSHD CTRL
KEMVC (N.m) 12.6 ± 8.8 B***,LG***,F***,C*** 96.6 ± 60.0 C** 98.2 ± 56.4 C* 123.6 ± 78.2 164.6 ± 55.9
CIS Severity 34.4 ± 8.7 F*,C*** 33.2 ± 10.5 F**,C*** 34.4 ± 10.9 C*** 43.0 ± 5.3 C*** 14.1 ± 6.1
VAS Pain 2.5 ± 1.6 C** 3.5 ± 2.5 C*** 3.6 ± 2.8 C*** 3.9 ± 2.2 C*** 0.4 ± 0.7
NEADL 13.9 ± 6.0 B***,LG*,F***,C*** 36.7 ± 14.4C*** 29.3 ± 7.1 C*** 39.4 ± 14.6C** 63.6 ± 3.1
Self-Efficacy 31.0 ± 6.2 28.3 ± 5.9 31.0 ± 5.1 30.7 ± 7.5 34.3 ± 4.3
Measures of Impairment and Perception
DMD Duchenne Muscular Dystrophy, BMD Beckers Muscular Dystrophy, LGMD Limb-Girdle Muscular Dystrophy, FSHD Facioscapulohumeral Muscular Dystrophy,
CIS Checklist Individual Strength, VAS Visual Analog Scale, KEMVC Knee Extension Maximal Voluntary Contraction, N.m Newton Metres, NEADL Nottingham
Extended Activities of Daily Living; B denotes significant difference from BMD; LG denotes significant difference from LGMD; F denotes significant difference from
FSHD; C denotes significant difference from CTRL; * denotes significance P < .05; ** denotes significance P < .01; *** denotes P < .001
Table 2 SF-36v2 in MD classifications
DMD BMD LGMD FSHD CTRL
Physical Function 1.3 ± 3.5 B**,F**,C*** 18.4 ± 18.2 C*** 6.3 ± 10.3C*** 18.2 ± 12.5 C*** 95.9 ± 9.3
Role Physical 72.1 ± 26.1 F*,C** 53.8 ± 32.5 C*** 59.9 ± 31.5 C*** 41.5 ± 26.7 C*** 99.2 ± 2.1
Bodily Pain 66.1 ± 16.4C* 58.6 ± 22.2C** 56.1 ± 24.4C** 48.1 ± 28.6C*** 87.1 ± 15.8
General Health 55.6 ± 20.1 C** 48.4 ± 19.3 C*** 43.3 ± 22.5 C*** 44.1 ± 24.2 C*** 81.7 ± 11.2
Vitality 63.3 ± 18.0F*** 50.0 ± 24.7C* 51.6 ± 17.3 37.9 ± 16.9C*** 72.3 ± 19.2
Social Function 84.1 ± 41.9C* 68.8 ± 30.4 C** 76.0 ± 27.4 C* 67.9 ± 29.7 C** 97.7 ± 6.8
Role Emotional 80.6 ± 24.5C* 66.2 ± 32.6 C** 86.8 ± 25.7 F* 69.0 ± 24.1 C** 98.4 ± 4.5
Mental Health 79.0 ± 14.9 F* 74.2 ± 16.0 C* 78.8 ± 14.6 65.0 ± 19.1C** 84.7 ± 8.5
Total Physical Score 34.3 ± 5.4 C*** 34.5 ± 6.7 C*** 30.2 ± 5.8 C*** 30.8 ± 6.3 C*** 56.8 ± 3.6
Total Mental Score 58.2 ± 10.5 51.8 ± 9.3 58.3 ± 9.7 49.8 ± 11.0 55.8 ± 3.6
SF36 outcomes. Presented as mean ± SD
DMD Duchenne Muscular Dystrophy, BMD Becker’s Muscular Dystrophy, LGMD Limb-Girdle Muscular Dystrophy, FSHD Facioscapulohumeral Muscular Dystrophy;
B denotes significant difference from BMD; LG denotes significant difference from LGMD; F denotes significant difference from FSHD; C denotes significant
difference from CTRL; * denotes significance <.05; ** denotes significance <.01; *** denotes significance <.001
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The Vitality domain was moderately associated with
CIS Severity in DMD. BMD moderately associated both
CIS Severity and VAS Pain with the Vitality domain.
Both Vitality and Social Function domains were moder-
ately associated with CIS Severity in FSHD.
The Role Emotional domain was moderately associ-
ated with Self-Efficacy in DMD and BMD, respectively.
In addition, Role Emotional domain was associated with
CIS Severity in DMD (moderate) and FSHD (strong).
The Mental Health domain was moderately associated
with CIS Severity in both BMD and FSHD.
Total Physical Score was moderately associated with
CIS Severity in BMD, while VAS Pain was associated
with Total Physical Score in both BMD (weak) and
FSHD (moderate). Total Mental Score showed strong
associations with CIS Severity in FSHD.
Discussion
The present study assesses QoL across four separate
classifications of adults with MD, as well as presenting a
range of factors that are associated with QoL. The find-
ings show that adults with MD typically reported poorer
QoL when compared with CTRL. Furthermore, the QoL
of adults with different classifications of MD were largely
comparable with the exception of physical function and
mental wellbeing domains. The findings highlight that
despite progressive muscle weakness being a defining
characteristic of MD it is not consistently associated
with QoL in adults with MD; specifically, KEMVC was
associated with 2/10 domains in BMD only. By contrast,
QoL domains were more frequently associated with
ADLs (4/10 in DMD), pain (4/10 in BMD, 2/10 in
FSHD), and self-efficacy (4/10 in DMD, 1/11 in BMD
and FSHD). CIS Severity was the most consistent associ-
ate of QoL in adults with DMD (4/10 domains), BMD
(4/10), LGMD (1/10) and FSHD (6/10 domains). In
addition, higher BMI appeared a consistent negative
associate of QoL in adults with LGMD (3/10).
The poorer QoL observed in adults with MD is con-
sistent with other reports of MD and in other conditions
with impaired physical function [13, 14, 20, 62]. In the
present study however, differences between the QoL of
adults with different classifications of MD in domains
other than physical function were identified; this sug-
gests grouping MD conditions [14, 21, 63], or even more
broadly generalising into “muscle disease”, may lead to
errors of interpretation regarding QoL [15, 22, 26].
Unsurprisingly, differences in Physical Function ap-
peared consistent with the clinical progression of each
individual condition [3]. As would be expected given the
severity of the condition, DMD scored lowest for phys-
ical function [23, 64]. Despite the lower Physical Func-
tion score, DMD scored higher than FSHD across
Vitality, Role Physical and Mental Health domains. It is
Table 4 Associations of domains of SF-36v2
SF-36v2 BMI KEMVC NEADL CIS Severity VAS Pain Self-Efficacy
Physical Function – .609B** .595D*
.654B**
.751F**
– – –
Role Physical – – – −.769 D**
-.759F**
– .534D*
Bodily Pain – – .613D* – -.715B**
-.694F**
–
General Health – – .564D* -.525D*
-.620B**
-.644LG*
-.602B** –
Vitality -.800LG** – .533D* -.548D*
-.533B*
-.668F**
-.558B* .590D*
.541F*
Social Function -.643LG* .544B* – -.594F* – –
Role Emotional – – – -.544D*
-.851F***
– .570D*
.600B**
Mental Health – – – -.588B*
-.575F*
– –
Total Physical Score – – – -.597B** -.476B*
-.683F**
–
Total Mental Score -.748LG** – – -.884F** – –
Associations of SF-36v2 domains
BMI Body Mass Index, KEMVC Knee Extension Maximal Voluntary Contraction, NEADL Nottingham Extended Activities of Daily Living, CIS Checklist Individual
Strength, VAS Visual Analog Scale; D denotes significant association in DMD; B denotes significant association in BMD; LG denotes significant association in LGMD;
F denotes significant association in FSHD; − denotes no significant associations; * denotes association of <.05; ** denotes association of <.01; *** denotes
association of <.001
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possible that this could be attributed to better coping
mechanisms within DMD, as has been suggested previ-
ously in adolescents with DMD [65], with psychosocial-
adjustment to living reported previously in adolescents
with DMD [66] and adults living with chronic illnesses
[67]. Adults with FSHD may be less likely to have these
coping mechanisms, possibly due to the later onset of
the condition [68], leading to large changes in individ-
ual’s lives and possible comparisons to an individual’s
pre-condition state. By comparison, DMD is a life-long
condition [7], therefore acceptance of the condition and
limitations may be easier or occur earlier. Interestingly
though, adults with FSHD also scored lower than adults
with LGMD for Role Emotional and Mental Health do-
mains, despite both conditions having a characteristically
later onset [1]. Nonetheless, these assumptions are
speculative and require greater investigation beyond the
scope of the present study.
Within MD, the level of physical impairment is typically
seen as the defining characteristic of the condition [69],
and was theorised as a key associate of QoL. KEMVC was
however, only associated with Physical Function and So-
cial Function domains in adults with BMD. Previous re-
search has shown no association between the Physical
Function domain and respiratory function in adults with
DMD [24], however within ambulant children with DMD,
KEMVC was shown as a good predictor of QoL deter-
mined Physical Function [18]. The Physical Function do-
main showed more consistent associations with ADL
across conditions, which can be interpreted in two ways;
firstly, that an individual’s level of independence, rather
than function, influences QoL; and/or, secondly, that the
physical function assessment of the SF-36v2 is an assess-
ment of physical independence, rather than function. This
is furthered by the reflection of the Physical Function
scores upon ambulatory status, suggesting the Physical
Function domain may be less appropriate for non-
ambulant individuals [70], rather, the present authors sug-
gest further development and validation of the SF-36
walk-wheel [71]. Furthermore, the use of a single strength
measure of KEMVC, previously identified as relevant to
ADLs of high intensity, are beyond the capacity of many
adults with MD [72]. KEMVC may not be as relevant to
QoL in adults with MD particularly those who are non-
ambulatory. The associations of ADL with QoL, especially
in adults with DMD, signifies that being able to undertake
broader aspects of daily life (potentially using adaptive
measures), rather than lower limb function (i.e. KEMVC),
has a positive influence on QoL in DMD. The provision of
support to empower adults with DMD to be able to
undertake daily tasks should therefore be considered es-
sential for the maintenance of their QoL.
Pain and fatigue levels are higher in MD groups than
CTRL within the present study, consistent with those
that have previously identified pain and fatigue in adults
with FSHD and DMD [13, 16, 25]. The elevated pain
and fatigue levels in BMD and LGMD adults are how-
ever, comparable to DMD and FSHD adults, suggesting
that fatigue and pain may be symptomatic of MD rather
than within specific conditions [73, 74]. The elevated
fatigue of adults with FSHD in comparison to other MD
groups as well as CTRL identifies a condition specific
need for further investigation and condition specific
interventions [53]. Furthermore, the consistent associa-
tions of fatigue and pain across the present MD condi-
tions with aspects of QoL highlights their impact on
both physical and mental well-being [53]. Similar associ-
ations between pain and fatigue have been identified in
other clinical conditions [33, 75], as well as in adults
with DMD and FSHD [16, 35]. This finding suggests that
interventions that are known to reduce pain and fatigue
in other clinical conditions (e.g. acupuncture [76],
physiotherapy [77, 78], and physical activity, as has been
applied in FSHD [54]), could improve QoL in adults
with MD, however there is currently a lack of research
associated with pain and fatigue management in these
conditions [79, 80].
No differences between any of the present MD condi-
tions and CTRL were observed for self-efficacy, which
would appear as a positive outcome with physical mani-
festations of MD appearing to not influence an individ-
ual’s confidence to overcome problems. Interestingly
however, self-efficacy was positively associated with QoL
domains, particularly within the DMD group. The
authors propose this could be attributed to the severe
loss of physical function associated with DMD [23],
subsequently individuals may develop higher problem
solving and coping capabilities, resulting in higher Role
Physical, Role Emotional and Vitality domains evidenced
in the current study. Further interventions in the treat-
ment strategy of those with DMD, and more broadly all
of the MDs, should address the psychosocial issues iden-
tified in the present study, as they suggest possible
improvements in the QoL of adults with MD.
Despite wide variance in the physical manifestation of
these MD conditions, we show that all have lower QoL
compared to CTRL, with some specific differences
between MD classifications in individual domains of
QoL. The largest differences in QoL between MD classi-
fications were between the Physical Function domain,
consistent with the classical definitions of these conditions
[3], other differences were however, identified between
classifications across domains associated with mental
and psychological wellbeing. This finding suggests
that grouping these forms of MD together when
examining QoL [14] is not appropriate given the spe-
cific differences identified. Independently, a range of
variables were associated with QoL domains, with the
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most frequent associations being found with activities
of daily living, self-efficacy and pain; it was however,
fatigue that was most consistently associated with
multiple QoL domains, across all MD conditions.
Study limitations
This study has two main limitations. First, MD partici-
pants were recruited from a specialist centre, where par-
ticipants attended regular physiotherapy and condition
management. This could be considered a limitation as to
attend a specialist centre participants must be referenced
by a clinician, and are therefore more likely to already be
experiencing weakness, pain or fatigue, likely affecting
their QoL, predisposing the associations identified. Fur-
thermore, it is likely that there are shared characteristics
of participants who are regular users of the same special-
ist centre, which, for example, may explain why no asso-
ciations were identified between variables and social
function, given that many are also likely to be in the
same or similar social circles. The use of health and
rehabilitation centres have always been a focal point for
clinical and neuromuscular research, and help to over-
come issues of mobility and access when recruiting
adults with neuromuscular conditions [28, 81]. Further-
more, our fatigue and pain data remains comparable
with that previously reported [16, 25, 82]. Secondly,
this study is cross-sectional, and while able to identify
issues with QoL, future research is required to
address the longitudinal changes associated with
progressive conditions.
Conclusion
Differences identified in domains of QoL in the present
investigation suggests a greater focus is required, and
further investigation is needed into mental health and
wellbeing, particularly in conditions such as FSHD. It is
proposed that later onset of this condition may have a
large impact on psychosocial aspects associated with
QoL. Furthermore, ADLs were only associated with QoL
domains, other than Physical Function, in adults with
DMD, highlighting the importance of independence in
this condition. In addition, consistent associations of
pain and fatigue across QoL domains, across MD
classifications, indicates a need for future investigation
into the management and treatment of pain and fatigue
within adults with MD.
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